Huntington’s disease symptoms reduced by new peptide-polymer therapy

Nov 04, 2024

Carolyn Marks and Joel Svensson

In this interview, conducted at SfN 2024 in Chicago, News Medical speaks with Joel Svensson and Carolyn Marks of Atlas Antibodies, about their new launch, the MolBoolean™, as well as how conferences like SfN are helping shape the future of neuroscience research.

Previous: Examining prestructured β-actin peptides as substrates of histidine methyltransferase SETD3 | Scientific Reports Next: Identification of virus epitopes and reactive T-cell receptors from memory T cells without peptide synthesis | Communications Biology

Send inquiry

Send